BeiGene to Present Clinical Data on BRUKINSA in Chronic Lymphocytic Leukemia at the 63rd ASH Annual MeetingBusiness Wire • 11/04/21
BeiGene and Nanolek Announce Approval in Russia for BRUKINSA® (Zanubrutinib) for Treatment of Patients with Relapsed or Refractory Mantle Cell LymphomaBusiness Wire • 10/20/21
BeiGene Announces BRUKINSA® (Zanubrutinib) Approved for Treatment of Patients with Mantle Cell LymphomaBusiness Wire • 10/10/21
BeiGene Announces BRUKINSA® (Zanubrutinib) Approved for Treatment of Patients with Mantle Cell Lymphoma in AustraliaBusiness Wire • 10/10/21
BeiGene Announces First Regulatory Approval in Australia for BRUKINSA® (Zanubrutinib) for Treatment of Patients with Waldenström's MacroglobulinemiaBusiness Wire • 10/07/21
BeiGene Receives Positive CHMP Opinion for BRUKINSA® (Zanubrutinib) for the Treatment of Adults with Waldenström's MacroglobulinemiaBusiness Wire • 09/17/21
U.S. FDA Grants BRUKINSA® (Zanubrutinib) Accelerated Approval in Relapsed or Refractory Marginal Zone LymphomaBusiness Wire • 09/15/21
BeiGene Announces U.S. FDA Acceptance of Biologics License Application for Tislelizumab in Esophageal Squamous Cell CarcinomaBusiness Wire • 09/13/21
BeiGene to Present Latest Findings in Robust Lung Cancer Portfolio at ESMO Congress 2021Business Wire • 09/12/21
U.S. FDA Grants BRUKINSA® (Zanubrutinib) Approval in Waldenström's MacroglobulinemiaBusiness Wire • 09/01/21
BeiGene Announces Acceptance of a Supplemental Biologics License Application in China for Tislelizumab in Nasopharyngeal CancerBusiness Wire • 08/22/21
BeiGene Announces Acceptance by Swissmedic of Marketing Authorization Application for BRUKINSA® (Zanubrutinib) in Waldenström's MacroglobulinaemiaBusiness Wire • 08/18/21
BeiGene and EUSA Pharma Announce China NMPA Approval of QARZIBA® (Dinutuximab Beta) for Patients with High-Risk NeuroblastomaBusiness Wire • 08/17/21